These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34073205)

  • 1. AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.
    Hanekamp D; Tettero JM; Ossenkoppele GJ; Kelder A; Cloos J; Schuurhuis GJ
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia.
    Terwijn M; Kelder A; Snel AN; Rutten AP; Scholten WJ; Oussoren YJ; Van De Loosdrecht AA; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Int J Lab Hematol; 2012 Aug; 34(4):432-41. PubMed ID: 22471741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of measurable residual disease based on multiparameter flow cytometry in childhood acute myeloid leukemia.
    Huo Y; Guan XM; Dou Y; Wen XH; Guo YX; Shen YL; An XZ; Yu J
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Nov; 23(11):1111-1118. PubMed ID: 34753542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
    Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf Å; Deneberg S; Jädersten M; Antunovic P; Cammenga J; Möllgård L; Wennström L; Ölander E; Ehinger M; Fogelstrand L; Höglund M; Lazarevic VL
    Leuk Lymphoma; 2021 Aug; 62(8):1973-1981. PubMed ID: 33719843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia.
    Kamel AM; Elsharkawy NM; Kandeel EZ; Hanafi M; Samra M; Osman RA
    Front Oncol; 2022; 12():867684. PubMed ID: 35530356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia.
    Ahmed S; Elsherif M; Yassin D; Elsharkawy N; Mohamed AS; Yasser N; Elnashar A; Hafez H; Kolb EA; Elhaddad A
    Front Oncol; 2024; 14():1340909. PubMed ID: 38720804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
    Schuurhuis GJ; Heuser M; Freeman S; Béné MC; Buccisano F; Cloos J; Grimwade D; Haferlach T; Hills RK; Hourigan CS; Jorgensen JL; Kern W; Lacombe F; Maurillo L; Preudhomme C; van der Reijden BA; Thiede C; Venditti A; Vyas P; Wood BL; Walter RB; Döhner K; Roboz GJ; Ossenkoppele GJ
    Blood; 2018 Mar; 131(12):1275-1291. PubMed ID: 29330221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
    Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
    Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
    Tettero JM; Al-Badri WKW; Ngai LL; Bachas C; Breems DA; van Elssen CHMJ; Fischer T; Gjertsen BT; van Gorkom GNY; Gradowska P; Greuter MJE; Griskevicius L; Juliusson G; Maertens J; Manz MG; Pabst T; Passweg J; Porkka K; Löwenberg B; Ossenkoppele GJ; Janssen JJWM; Cloos J
    Front Oncol; 2022; 12():999822. PubMed ID: 36300090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of
    Grob T; Sanders MA; Vonk CM; Kavelaars FG; Rijken M; Hanekamp DW; Gradowska PL; Cloos J; Fløisand Y; van Marwijk Kooy M; Manz MG; Ossenkoppele GJ; Tick LW; Havelange V; Löwenberg B; Jongen-Lavrencic M; Valk PJM
    J Clin Oncol; 2023 Feb; 41(4):756-765. PubMed ID: 36315929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
    Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
    Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.
    Caballero-Velázquez T; Pérez-López O; Yeguas Bermejo A; Rodríguez Arbolí E; Colado Varela E; Sempere Talens A; Vidriales MB; Solé-Rodríguez M; Quirós Caso C; Pérez López E; Reinoso Segura M; Prats-Martín C; Montesinos P; Pérez-Simón JA
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods of Detection of Measurable Residual Disease in AML.
    Zhou Y; Wood BL
    Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors.
    Narlı Özdemir Z; Şahin U; Dalva K; Baltacı MA; Uslu A; Öztürk C; Cengiz Seval G; Toprak SK; Kurt Yüksel M; Topçuoğlu P; Arslan Ö; Özcan M; Beksaç M; İlhan O; Gürman G; Civriz Bozdağ S
    Turk J Haematol; 2021 Jun; 38(2):111-118. PubMed ID: 33112099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Minimal residual disease in AML].
    Taga T
    Rinsho Ketsueki; 2020; 61(4):343-349. PubMed ID: 32378579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.